• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病毒感染后出现的伴有抗3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)抗体的免疫介导坏死性肌病,与他汀类药物使用无关:一例报告

Immune-Mediated Necrotizing Myopathy With Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Antibodies Following Viral Infection and Without Association With Statin Use: A Case Report.

作者信息

Ferreira Pedro, Dâmaso Francisca, Anastácio Marta, Pinto Fausto, Lynce Ana

机构信息

Internal Medicine, Hospital de São Francisco Xavier, Lisbon, PRT.

Physiopathology, Lisbon School of Medicine, Lisbon, PRT.

出版信息

Cureus. 2024 Sep 26;16(9):e70281. doi: 10.7759/cureus.70281. eCollection 2024 Sep.

DOI:10.7759/cureus.70281
PMID:39463677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11512659/
Abstract

Immune-mediated necrotizing myopathy (IMNM) is a rare form of inflammatory myopathy characterized by severe muscle weakness, elevated serum creatine kinase (CK) levels, and myofiber necrosis with minimal inflammatory infiltrates. IMNM is frequently associated with autoantibodies, particularly anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and is often linked to statin use. However, it can also develop in statin-naïve patients, especially following viral infections. We present the case of a 47-year-old woman who developed anti-HMGCR-positive IMNM without prior statin exposure, following a viral respiratory infection and subsequent dengue fever. She initially presented with proximal muscle weakness and elevated CK levels, which worsened after contracting dengue. Diagnostic testing confirmed the presence of anti-HMGCR antibodies, and a muscle biopsy revealed necrotizing myopathy. Treatment with methylprednisolone, intravenous immunoglobulin, and rituximab resulted in significant clinical improvement. This case underscores the need to consider IMNM in patients with unexplained muscle weakness and elevated CK levels, even in the absence of statin use. Viral infections may trigger IMNM, highlighting the importance of early recognition and aggressive immunosuppressive therapy to prevent severe complications. Further research is required to better understand the pathophysiology of IMNM and optimize treatment approaches.

摘要

免疫介导的坏死性肌病(IMNM)是一种罕见的炎性肌病,其特征为严重肌无力、血清肌酸激酶(CK)水平升高以及肌纤维坏死伴少量炎性浸润。IMNM常与自身抗体相关,尤其是抗3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)抗体,且常与他汀类药物的使用有关。然而,它也可在未使用过他汀类药物的患者中发生,尤其是在病毒感染后。我们报告一例47岁女性病例,该患者在发生病毒性呼吸道感染及随后的登革热后,未接触过他汀类药物却患上了抗HMGCR阳性的IMNM。她最初表现为近端肌无力和CK水平升高,感染登革热后病情加重。诊断性检查证实存在抗HMGCR抗体,肌肉活检显示为坏死性肌病。采用甲泼尼龙、静脉注射免疫球蛋白和利妥昔单抗治疗后,临床症状有显著改善。该病例强调,即使在未使用他汀类药物的情况下,对于原因不明的肌无力和CK水平升高的患者也需考虑IMNM。病毒感染可能引发IMNM,这凸显了早期识别和积极免疫抑制治疗以预防严重并发症的重要性。需要进一步研究以更好地理解IMNM的病理生理学并优化治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/189e/11512659/03d7c85a716f/cureus-0016-00000070281-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/189e/11512659/07e48f160f9c/cureus-0016-00000070281-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/189e/11512659/03d7c85a716f/cureus-0016-00000070281-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/189e/11512659/07e48f160f9c/cureus-0016-00000070281-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/189e/11512659/03d7c85a716f/cureus-0016-00000070281-i02.jpg

相似文献

1
Immune-Mediated Necrotizing Myopathy With Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Antibodies Following Viral Infection and Without Association With Statin Use: A Case Report.病毒感染后出现的伴有抗3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)抗体的免疫介导坏死性肌病,与他汀类药物使用无关:一例报告
Cureus. 2024 Sep 26;16(9):e70281. doi: 10.7759/cureus.70281. eCollection 2024 Sep.
2
Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins.免疫介导的肌病与抗 3-羟基-3-甲基戊二酰辅酶 A 还原酶抗体有关,是他汀类药物引起的坏死性肌病的一个新出现的原因。
Joint Bone Spine. 2014 Jan;81(1):79-82. doi: 10.1016/j.jbspin.2013.06.008. Epub 2013 Aug 13.
3
Immune-Mediated Necrotizing Myopathy.免疫介导性坏死性肌病。
Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6.
4
Dengue infection triggered immune mediated necrotizing myopathy in children: a case report and literature review.登革热感染引发儿童免疫介导坏死性肌病:病例报告及文献复习。
Pediatr Rheumatol Online J. 2022 Jun 7;20(1):40. doi: 10.1186/s12969-022-00699-2.
5
Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM) in a patient on long-term statins.长期服用他汀类药物患者的免疫介导性坏死性肌病(IMNM)的诊断和治疗挑战。
Rheumatol Int. 2023 Feb;43(2):383-390. doi: 10.1007/s00296-022-05230-0. Epub 2022 Oct 19.
6
Clinical associations of patients with anti-3-hydroxy-3-methylglutaryl CoA reductase antibody-associated immune-mediated necrotising myopathy.抗 3-羟基-3-甲基戊二酰辅酶 A 还原酶抗体相关免疫介导性坏死性肌病患者的临床关联。
Intern Med J. 2023 Oct;53(10):1846-1853. doi: 10.1111/imj.16004. Epub 2023 Jan 27.
7
Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.早期与晚期开始静脉注射免疫球蛋白治疗抗3-羟基-3-甲基戊二酰辅酶A还原酶免疫介导坏死性肌病患者的益处
Arthritis Care Res (Hoboken). 2024 Nov;76(11):1584-1592. doi: 10.1002/acr.25406. Epub 2024 Sep 11.
8
Absence of Pathogenic Mutations and Strong Association With HLA-DRB1*11:01 in Statin-Naïve Early-Onset Anti-HMGCR Necrotizing Myopathy.他汀类药物初治早发性抗 HMGC-R 坏死性肌病中无致病性突变且与 HLA-DRB1*11:01 强关联。
Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200285. doi: 10.1212/NXI.0000000000200285. Epub 2024 Aug 6.
9
Anti-HMGCR (Hydroxy-3-Methylglutaryl-CoA Reductase) Myopathy: A Rare Cause of Proximal Muscle Weakness.抗3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)肌病:近端肌无力的罕见病因。
Cureus. 2024 May 26;16(5):e61094. doi: 10.7759/cureus.61094. eCollection 2024 May.
10
The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01.首例报告的与抗羟甲基戊二酰辅酶A还原酶自身抗体及HLA DRB1*11:01相关的他汀类药物诱导的免疫介导坏死性肌病家族性病例。
Acta Clin Belg. 2024 Sep 16:1-5. doi: 10.1080/17843286.2024.2403694.

本文引用的文献

1
Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues.抗 HMGCR 免疫介导的坏死性肌病:解决尚存问题。
Autoimmun Rev. 2023 Dec;22(12):103468. doi: 10.1016/j.autrev.2023.103468. Epub 2023 Oct 24.
2
Immune-mediated necrotizing myopathy: Report of two cases.免疫介导的坏死性肌病:两例报告。
World J Clin Cases. 2023 May 26;11(15):3552-3559. doi: 10.12998/wjcc.v11.i15.3552.
3
Immune-mediated necrotizing myopathy (NAM) related to SARS-Cov-2 infection: a case report.与新型冠状病毒肺炎(SARS-CoV-2)感染相关的免疫介导坏死性肌病:一例报告
BMC Neurol. 2023 Mar 22;23(1):117. doi: 10.1186/s12883-023-03170-1.
4
Anti-HMGCR Myopathy without Exposure to Statins: A Case Report.未接触他汀类药物的抗3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)肌病:一例报告
EJIFCC. 2022 Dec 12;33(4):342-349. eCollection 2022 Dec.
5
Dengue infection triggered immune mediated necrotizing myopathy in children: a case report and literature review.登革热感染引发儿童免疫介导坏死性肌病:病例报告及文献复习。
Pediatr Rheumatol Online J. 2022 Jun 7;20(1):40. doi: 10.1186/s12969-022-00699-2.
6
Therapeutic management of immune-mediated necrotizing myositis.免疫介导性坏死性肌炎的治疗管理
Curr Treatm Opt Rheumatol. 2021 Jun;7(2):150-160. doi: 10.1007/s40674-021-00174-1. Epub 2021 Mar 29.
7
Peculiar clinicopathological features of immune-mediated necrotizing myopathies.免疫介导性坏死性肌病的独特临床病理特征。
Curr Opin Rheumatol. 2018 Nov;30(6):655-663. doi: 10.1097/BOR.0000000000000547.
8
Immune-Mediated Necrotizing Myopathy.免疫介导性坏死性肌病。
Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6.
9
Anti-HMGCR Myopathy.抗 HMGCR 肌病。
J Neuromuscul Dis. 2018;5(1):11-20. doi: 10.3233/JND-170282.
10
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.坏死性自身免疫性肌病的临床特征和治疗结局。
JAMA Neurol. 2015 Sep;72(9):996-1003. doi: 10.1001/jamaneurol.2015.1207.